Do you want to read an article? Please log in or register.
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
Lancet Respir Med.
Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG
doi: 10.1016/
Pulmonary Fibrosis
Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study
Lancet Respir Med.
Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, Bhangale TR, Brauer MJ, Hunkapiller J, Reeder J, Mukhyala K, Cuenco K, Tom J, Cowgill A, Vogel J, Forrest WF, Collard HR, Wolters PJ, Kropski JA, Lancaster LH, Blackwell TS, Arron JR, Yaspan BL
doi: 10.1016/S2213-
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
RECOMMENDED
Pulmonary Hypertension
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Maron BA, Brittan EL, Hess E, Waldo SW, Barón AE, Huang S, Goldstein RH, Assad T, Wertheim BM, Alba GA, Leopold JA, Olschewski H, Galiè N, Simonneau G, Kovacs G, Tedford RJ, Humbert M, Choudhary G
doi: 10.1016/S2213-2600(20)30317-9.
Pulmonary Fibrosis
The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study
Eur Respir J.
Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C
doi: 10.1183/13993003.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V
doi: 10.1016/S2213-2600(20)30122-3.
RECOMMENDED
Pulmonary Fibrosis
Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study
Eur Respir J.
Nolan CM, Maddocks M, Maher TM, Banya W, Patel S, Barker RE, Jones SE, George PM, Cullinan P, Man WD
doi: 10.1183/13993003.
RECOMMENDED
Pulmonary FibrosisPulmonary Hypertension
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Behr J, Nathan SD, Wuyts WA, Mogulkoc Bishop N, Bouros DE, Antoniou K, Guiot J, Kramer MR, Kirchgaessler KU, Bengus M, Gilberg F, Perjesi A, Harari S, Wells AU
doi: 10.1016/S2213-2600(20)30356-8.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Pulmonary Fibrosis
Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS
doi: 10.1016/j.chest.2020.02.009.